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1. Introduction
The palatability of the active ingredient of a drug is a significant obstacle in developing a
patient friendly dosage form. Organoleptic properties, such as taste, are an important factor
when selecting a certain drug from the generic products available in the market that have the
same active ingredient. It is a key issue for doctors and pharmacists administering the drugs
and particularly for the pediatric and geriatric populations. Nowadays, pharmaceutical
companies are recognizing the importance of taste masking and a significant number of
techniques have been developed for concealing the objectionable taste [1].
The word “medicine” for a child is considered a bad thing to administer because of its aversive
taste. Medicines dissolve in saliva and bind to taste receptors on the tongue giving a bitter,
sweet, salty, sour, or umami sensation. Sweet and sour taste receptors are concentrated on the
tip and lateral borders of the tongue respectively. Bitter taste is sensed by the receptors on the
posterior part of the tongue and umami taste receptors are located all over the tongue. A short
period after birth, infants reject bitter tastes and prefer sweet and umami tastes[1]. Children
have larger number of taste buds than adults which are responsible for sensitivity toward taste.
These taste buds regenerate every two weeks. Taste becomes altered as a function of the aging
process, which explains why most children find certain flavors to be too strong when adults
do not. The American Academy of Pediatrics estimates that compliance in children is as low
as 53%, indicating that children frequently fail to take medications properly. Noncompliance
can lead to: (1)persistent symptoms, (2) need for additional doctor visits or even hospitaliza‐
tions, (3) worsening of condition, (4) need for additional medications, (5) increased healthcare
costs and (6) development of drug-resistant organisms in cases of infectious diseases [2].
In mammals, taste buds are groups of 30-100 individual elongated "neuroepithelial" cells which
are often embedded in special structure in the surrounding epithelium known as papillae. Just
below the taste bud apex, taste cells are joined by tight junctional complexes that prevent gaps
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between cells. Food molecules cannot therefore squeeze between taste cells and get into the
taste bud.
Taste papillae located on the tongue appear as little red dots, or raised bumps, particularly at
the front of the tongue called "fungi form" papillae. There are three other kinds of papillae,
foliate, circumvallates and the non-gustatory fili form. In mammals taste buds are located
throughout the oral cavity, in the pharynx, the laryngeal epiglottis and at the entrance of the
esophagus. Taste perception fades with age; on average, people lose half their taste receptors
by time they turn 20 [3].The sensation of taste can be categorized into five basic tastes:
sweetness, sourness, saltiness, bitterness, and umami. Taste buds are able to differentiate
among different tastes through detecting interaction with different molecules or ions. Sweet,
umami, and bitter tastes are triggered by the binding of molecules to G protein-coupled
receptors on the cell membranes of taste buds. Saltiness and sourness are perceived when alkali
metal or hydrogen ions enter taste buds, respectively [4].As taste senses both harmful and
beneficial things, all basic tastes are classified as either aversive or appetitive, depending upon
the effect the things they sense have on our bodies [5].Sweetness helps to identify energy-rich
foods, while bitterness serves as a warning sign of poisons [6].
For a long period, it was commonly accepted that there is a finite and small number of "basic
tastes" of which all seemingly complex tastes are ultimately composed. As of the early
twentieth century, physiologists and psychologists believed there were four basic tastes:
sweetness, sourness, saltiness, bitterness. At that time umami was not proposed as a fifth taste
but now a large number of authorities recognize it as the fifth taste [7]. In Asian countries
within the sphere of mainly Chinese and Indian cultural influence, pungency (piquancy or
hotness) had traditionally been considered a sixth basic taste. Today, the consensus is that
sweet,amino acid (umami), and bitter taste converge one common transduction channel, the
transient receptor potential channel TRPM5, via phospholipase C (PLC). TRPM5 is a newly
discovered TRP related to other channels in sensory signaling systems. It has been shown that
PLC, a major signaling effect or of G-protein coupled receptors (GPCRs), and TRPM5 are co
expressed with T1Rs and T2Rs and are vital for sweet, amino acid, and bitter taste transduction.
Activation of T1R or T2R receptors by their respective taste molecules would stimulate G
proteins, and in turn PLC (PLC-ß2). The activation of PLC generates two intracellular mes‐
sengers-IP3 and di-acyl glycerol (DAG)-from the hydrolysis of phosphatidylinositol-4,5-
bisphosphate (PIP2)and opens the TRPM5 channel, resulting in the generation of a
depolarizing receptor potential. Other additional pathways may modulate sweet, amino acid,
or bitter taste reception but would not, themselves, trigger a taste response. It is not at present
known how PLC activates TRPM5 or whether DAG is involved [8-18].
2. Taste masking
There are numerous pharmaceutical and over the counter (OTC) preparations that contain
active ingredients, which are bitter in taste. With respect to OTC preparations, such as cough
and cold syrups, the bitterness of the preparation leads to lack of patient compliance. Among
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examples that are commonly used drugs with bitter taste: (1) pseudoephedrine (1) (Figure
1),a sympathomimetic drug of the phenethylamine (2) (Figure 1) and amphetamine (3) (Figure
1) chemical classes. It may be used as a nasal/sinus decongestant, as a stimulant, or as a
wakefulness-promoting agent [19], (2) dextromethorphan (4) (Figure 1), an antitussive (cough
suppressant) drug. It is one of the active ingredients in many over-the-counter cold and cough
medicines. Dextromethorphan has also found other uses in medicine, ranging from pain relief
to psychological applications. It is sold in syrup, tablet, spray, and lozenge forms. In its pure
form, dextromethorphan occurs as a white powder [20], (3) dyphylline (5) (figure1) also known
as dipprophyllinea xanthine derivative withbronchodilatorandvasodilator effects. It is used
in the treatment of respiratory disorders like asthma, cardiac, and bronchitis. It acts as an
adenosine receptor antagonist and phosphodiesterase inhibitor [21].(4) phenylephrine (6)
(Figure 1), is a selective α1-adrenergic receptor agonist used primarily as a decongestant, as
an agent to dilate the pupil, and to increase blood pressure [22]. Phenylephrine is marketed as
a substitute for the decongestant pseudoephedrine, (5) chlorhexidine (7) (Figure 1), a chemical
antiseptic. It is effective on both Gram-positive and Gram-negative bacteria, although it is less
effective with some Gram-negative bacteria. It has both bactericidal and bacteriostatic
mechanisms of action, the mechanism of action being membrane disruption, not ATPase
inactivation as previously thought [23]. It is also useful against fungi and enveloped viruses,
though this has not been extensively investigated, (6) atorvastatin (8) (Figure 1), a member of
the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque
and prevents strokes through anti-inflammatory and other mechanisms. Like all statins,
atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that
plays a key role in production of cholesterol in the body [22], (7) loperamide (9) (Figure 1),a
piperidine derivative, is an opioid drug used against diarrhea resulting from gastroenteritis
or inflammatory bowel disease. In most countries it is available generically [24].(8) terfenadine
(10) (Figure 2), was an antihistamine formerly used for the treatment of allergic conditions. It
was brought to market by Hoechst Marion Roussel (now Sanofi-Aventis) and marketed under
various brand names. According to its manufacturer, terfenadine had been used by over 100
million patients worldwide as of 1990 [25]. It was superseded byfexofenadine (11) (Figure 2)
in the 1990s due to the risk of a particular type of disruption of the electrical rhythms of the
heart (specifically cardiac arrhythmia caused by QT interval prolongation) [22], (9) predniso‐
lone (12) (Figure 2), is a synthetic glucocorticoid, a derivative of cortisol, which is used to treat
a variety of inflammatory and auto-immune conditions. It is the active metabolite of the drug
prednisoneand is used especially in patients with hepatic failure, as these individuals are
unable to metabolize prednisone into prednisolone [22], (10) salbutamol (13) (Figure 2), or
albuterol (USAN) is a short-acting β2-adrenergic receptor agonist used for the relief of
bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease. It is
marketed as Ventolin among other brand names. Salbutamol was the first selective β2-receptor
agonist to be marketed – in 1968. It was first sold by Allen & Hanburys under the brand name
Ventolin. The drug was an instant success, and has been used for the treatment of asthma ever
since [26]. (11) guaifenisen (14) (Figure 2), or guaiphenesin (former BAN), also glyceryl
guaiacolate, is an expectorant drug sold over the counter and usually taken orally to assist the
bringing up (expectoration) of phlegm from the airways in acute respiratory tract infections
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[22] and (12) amoxicillin (15) (Figure 2), a moderate-spectrum, bacteriolytic, β-lactam antibiotic
used to treat bacterial infections caused by susceptible microorganisms. It is usually the drug
of choice within the class because it is better absorbed, following oral administration, than
other β-lactam antibiotics. Amoxicillin is one of the most common antibiotics prescribed for
children. The drug became available in 1972 [22].
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3. Challenges and criteria for pursuing masking bitter taste approaches
The most significant challenges that facing developers when pursuing masking bitter taste
drugs approaches are: (i) Safety, tolerability and efficacy of the compound which are based on
non-clinical testing, and physicochemical properties such as solubility, permeability and
stability, (ii) lack of robust and reliable techniques for early taste screening of compounds with
limited toxicity data, (iii) structure–taste relationships of pharmaceutically active molecules is
limited, (iv) The perception of taste of pharmaceuticals has been shown to be different between
adults and children and it might differ between healthy and patient children [4] and (v) ethical
concerns to perform taste studies in healthy children unless the study is a ‘swill and spit’ one
with drugs known to have a good safety profile [27-29].
4. Bitter taste masking approaches (techniques)
A variety of taste masking approaches has been used to address the patient compliance
problem.  With  strongly  bad  tasting  medications  even  a  little  exposure  is  sufficient  to
perceive the bad taste. Conventional taste masking methods such as the use of sweeten‐
ers, amino acids and flavoring agents alone are often inadequate in masking the taste of
highly bitter drugs. Drugs such as macrolide antibiotics,  non-steroidal anti-inflammatory
such as ibuprofen (16) (Figure 2), quinine (17) (Figure 2), celecoxib (18) (Figure 3), etoricox‐
ib (19) (Figure 3), levofloxacin (20) (Figure 3)and penicillins have a pronounced bitter taste
[30]. Masking the taste of water soluble bitter drugs, especially those given in high doses,
is difficult to achieve by using sweeteners alone. As a consequence, several approaches have
been investigated and have resulted in the development of more efficient techniques for
masking the bitter taste of active ingredients. All of the developed techniques are based on
the  physical  modification  of  the  formulation  containing  the  bitter  tastant.  Among  the
approaches used to mask bitter taste of pharmaceuticals are: (1) taste masking using flavors,
sweeteners, and amino acids. This technique is the foremost and the simplest approach for
taste masking, especially in the case of pediatric formulations, chewable tablets, and liquid
formulations.  However,  it  is  not  an ideal  to  be used for  highly bitter  and highly water
soluble drugs. An example for such approach is the use of monosodium glycyrrhizinate
together with flavors to mask the bitter taste of guaiphenesin (14) (an expectorant drug)
Taste masked lamivudine (antiretroviral drug) was prepared by using lemon, orange and
coffee flavors [3,31]; (2) taste masking with lipophilic vehicles such as: i) Lipids; acetamino‐
phen  granules  are  sprayed  with  molten  stearyl  stearate,  mixed  with  suitable  tablet
excipients,  and  incorporated  into  a  taste  masked,  chewable  tablet  formulation  and  (ii)
lecithin and Lecithin-like substances; formulations with lecithin or lecithin-like substances
in large quantities are believed to efficiently mask bitter taste of pharmaceuticals [3]. An
example of a drug formulation containing lecithin-like substance is the one composed of
magnesium aluminum silicate with soybean lecithin and talampicillin HCl (21) (antibiotic
drug) (Figure 3); (3) coating is one of the most efficient and commonly used taste mask‐
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ing techniques.  It  is  more efficient technology for aggressively bitter drugs even though
coating imperfections, if present, reduce the efficiency of the technique. Coating of tablets,
pellets  or  any  other  kind  of  particles  with  a  film-forming  polymer  is  a  successful  ap‐
proach to provide a physical barrier, concealing unpleasant odors and bitter taste. Addition‐
ally, it can prevent penetration of moisture into the formulation. Coating materials can be
selected from a wide range of hydrophobic and hydrophilic polymers such as polyvinylpyr‐
rolidone,  polyvinyl  alcohol  and cellulose  derivatives.  The  ideal  polymer  for  taste-mask‐
ing, odor suppression and moisture protection should prevent dissolution of the dosage
form in the mouth, but should be readily soluble in the stomach. Coating is classified based
on the type of coating material, coating solvent system, and the number of coating layers.
Taste masked famotidine (a drug for ulcer treatment) formulated by using a combination
of water soluble polymers like polyvinylpyrrolidone and insoluble polymers like cellulose
acetate is an example of such technique. Other various inert coating agents can be used to
coat  bitter  drugs.  These coating agents  simply provide a  physical  barrier  over  the drug
particles. Examples for such coating agents are starch, povidone, gelatin, methylcellulose,
ethyl cellulose and etc.  One of the most efficient Method of drug particle coating is  the
fluidized bed processor [4]. In this approach, powders as fine as 50 um are fluidized in an
expansion chamber by means of heated, high-velocity air, and the drug particles are coated
with  a  coating  solution  introduced  usually  from  the  top  as  a  spray  through  a  nozzle.
Increasing the length of the coating cycle can increase coating thickness. Taste masking of
Ibuprofen (16)(Figure 2) has been successfully achieved by this technique [4]; (4) microen‐
capsulation is  a  technique applicable  to  protect  materials  from oxidation,  volatilizing as
well as to mask their bitter tastes [6]. Microencapsulation processes are commonly based
on the principle of solvent extraction or evaporation. Microencapsulation as a process has
been defined by Bakan [6] as a means of applying relatively thin coating to small parti‐
cles of solid, droplets of liquid and dispersion. This process can be used for masking the
bitter  taste  of  drugs  by  microencapsulating  drug  particles  with  various  coating  agents.
Coating  agents  employed includes  gelatin,  povidone,  HPMC,  ethyl  cellulose,  Bees  wax,
carnauba wax, acrylics and shellac. Bitter-tasting drugs can be first encapsulated to produce
free  flowing  microcapsules,  which  are  then  blended  with  other  excipients  and  com‐
pressed into tablets. Microencapsulation also increases the stability of the drug. It can be
accomplished  by  a  variety  of  methods,  including  air  suspension,  coacervation-phase
separation,  spray  drying  and  congealing,  pan  coating,  solvent  evaporation  and  multi-
orifice  centrifugation  techniques;  (5)  taste  suppressants  and  potentiators  such  as  the
Linguagen’s  bitter  blockers  (e.g.  adenosine monophosphate)  are  used for  masking bitter
taste of various compounding by competing with the latter on binding to the G-protein
coupled  receptor  sites  (GPCR)  [32];  (6)  ion  exchange  resins  are  water  insoluble,  cross-
linked polymers containing salt forming groups in repeating position on the polymer chain.
Drug can be bound to the ion exchange resin by either repeated exposure of the resin to
the  drug in  a  chromatographic  column or  by prolonged contact  of  resin  with  the  drug
solution. The resins forms insoluble adsorbates or resinates through weak ionic bonding
with oppositely charged drugs.  The exchange of  counter ions from resin is  competitive.
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Most  of  the  bitter  drugs  have amine as  a  functional  group,  which is  the  cause of  their
obnoxious taste. If the functional groups are blocked by complex formation the bitterness
of the drug reduces drastically. A drug-resin complex is made from the bitter drugs and
ion-exchange resins. The nature of the drug-resin complex is such that the average pH of
6.7 and cation concentration of about 40 meq/ lit in saliva are not able to break the drug-
resin complex but it is weak enough to be broken down by the hydrochloric acid present
in the stomach. Thus the drug: resin complex is absolutely tasteless and stable,  with no
after taste, but at the same time its bioavailability is not affected. Ion exchange resin like
Amberlite was used to formulate taste masked fast dissolving orally consumable films of
dextromethorphan (cough suppressant drug) [33,34]; (7) inclusion complexes in which the
drug molecule fits  into the cavity of  a complexing agent forming a stable complex.  The
obtained complexing agent has the potential to mask the bitter taste of a drug by either
decreasing  its  oral  solubility  on  ingestion,  or  decreasing  the  amount  of  drug  particles
exposed  to  taste  buds,  thus  reducing  the  perception  of  bitter  taste.  The  inclusion  com‐
plexes with cyclodextrin owe their existence to van der Waals forces between the host and
guest.  Cyclodextrin  is  the  most  widely  used  complexing  agent  for  inclusion  type  com‐
plexes. It is a sweet, nontoxic, cyclic oligosaccharide derived from starch. Cyclodextrin forms
inclusion complexes with organic molecules both in solid state and in solution [35]; (8) pH
modifiers are capable of generating a specific pH microenvironment in aqueous media that
has the ability to facilitate in situ precipitation of the bitter drug compound in saliva thus
reducing  the  overall  taste  sensation  for  liquid  dosage  forms  like  suspension  [36];  (9)
adsorbates  which  are  commonly  used  with  other  taste  masking  technologies  to  mask
pharmaceuticals bitterness. The pharmaceutical may be adsorbed or/and entrapped in the
matrix of the adsorbate porous, which may result in a delayed release of the bitter tastant
during the passage through the oral cavity and hence achieving taste masking [37];  (10)
chemicals;  the  solubility  and  absorption  of  drugs  can  be  modified  by  the  formation  of
molecular  complexes.  Lowering  drug  solubility  through  molecular  complexation  can
decrease  the  intensity  of  bitterness.  Higuchi  and Pitman [38]  reported that  caffeine  (22)
(Figure 3) forms complexes with organic acids that are less soluble than xanthenes and as
such  can  be  used  to  decrease  the  bitter  taste  of  caffeine;  (11)  solid  dispersions;  solid
dispersion have been defined as dispersion of one or more active ingredients in an inert
carrier  or  matrix  at  solid  state  prepared  by  melting  (fusion)  solvent  or  melting  solvent
method. Solid dispersion is also called as co precipitates for those preparation obtained by
solvent method such as co precipitates of sulphathiazole (23) (Figure 3) and povidone. Solid
dispersions using insoluble matrices or bland matrices may be used to mask the bitter taste
of drugs. Also using them as absorbates on various carriers may increase the stability of
certain drugs [39]; (12) multiple emulsions; a novel technique for taste masking of drugs
employing multiple emulsions has been prepared by dissolving drug in the inner aque‐
ous phase of w/o/w emulsion under conditions of good shelf stability. The formulation is
designed to release the drug through the oil phase in the presence of gastrointestinal fluid
[40];  (13) using liposomes is another way of masking the unpleasant taste of therapeutic
agent  is  to  entrap  them  into  liposome.  For  example,  incorporating  it  into  a  liposomal
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formulation prepared with egg phosphatidyl choline masked the bitter taste of an antima‐
larial,  chloroquine  phosphate(24)  (Figure  4)in  HEPES  (N-2-hydroxyetylpiperzine-N’-2-
ethane sulfonic acid) buffer at pH 7.2 [41];and (14) prodrugs;  chloramphenicol palmitate
ester (25)  (Figure 4),  clindamycin palmitate ester (26)  (Figure 4)and triamcinolone diace‐
tate ester (27)(Figure 4) [42].
T
erfenedine (10)
N
OH
OH
N
OH
OH O
OH
Fexofenadine (11)
O
OH
O
HO
H
HO
H
H
Prednisolone (12)
HO
HO
HN
OH
Salbutamol (13)
O
O OH
OH
Guaifenesin (14)
N
S
O
OH
O
H
N
H
O
NH2
HO
Amoxicillin (15)
OH
O
Ibuprofen (16)
N
OCH3
OH
N
Quinine (17)
Figure 2. Chemical structures for 10-17.
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Although  the  mentioned  approaches  have  helped  to  improve  the  taste  of  some  drugs
formulations, the problem of the bitter taste of drugs in pediatric and geriatric formula‐
tions still  creates a serious challenge to pharmacists.  Thus, different strategies should be
developed  in  order  to  overcome  this  serious  problem.  The  novel  chemical  approach
discussed  in  this  chapter  involves  the  design  of  prodrugs  for  masking  bitter  taste  of
pharmaceuticals based on intramolecular processes using density functional theory (DFT)
and ab initio methods [43] and correlations of experimental and calculated reactions rates.
No enzyme is  needed to catalyze the interconversion of  a  prodrug to its  corresponding
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drug. The rate of drug release is controlled by the nature of the linker bound to the drug.
Bitter  tastant  molecules  interact  with  taste  receptors  on the  tongue to  give  bitter  sensa‐
tion. Altering the ability of the drug to interact with bitter taste receptors could reduce or
eliminate  its  bitterness.  This  could  be  achieved  by  an  appropriate  modification  of  the
structure and the size of a bitter compound. Bitter molecules bind to the G-protein coupled
receptor-type T2R on the apical membrane of the taste receptor cells located in the taste
buds [44,45].
Due to the large variation of structural features of bitter tasting molecules, it is difficult to
generalize the molecular requirements for bitterness. Nevertheless, it was reported that a
bitter tastant molecule requires a polar group and a hydrophobic moiety. A quantitative
structure activity relationship (QSAR) model was developed and has been established for
the prediction of bitterness of several tastant analogues. For example, it was reported that
the addition of a pyridinium moiety to an amino acid chain of a variety of bitter amino
acid  compounds  decreases  bitterness,  such  as  in  the  case  of  glycine.  Other  structural
modifications, such as an increase in the number of amino groups/residues to more than 3
and a reduction in the poly-hydroxyl group/ COOH, have been proven to decrease bitterness
significantly.  Moreover,  changing the configuration of  a  bitter  tastant  molecule by mak‐
ing isomer analogues was found to  be  important  for  binding affinity  to  enhance bitter‐
ness agonist activity (e.g. L-tryptophan is bitter while D-tryptophan is sweet) [46].
Our  recent  studies  on  intramolecularity  have  demonstrated  that  there  is  a  necessity  to
further explore the mechanisms for the intramolecular processes to be utilized in the design
for  determining  the  factors  playing  dominant  role  in  determining  the  reaction  rate.
Unraveling  the  reaction  mechanism  would  allow  for  an  accurate  design  of  an  efficient
chemical  device to be used as a prodrug linker that  can be covalently linked to a drug
which can chemically, and not enzymatically be cleaved to release the active parent drug
in  a  controlled  manner.  For  instance,  exploring  the  mechanism for  a  proton transfer  in
Kirby’s  acetals  [47]  has  led to  a  design and synthesis  of  novel  prodrugs  of  aza-nucleo‐
sides to treat myelodysplastic syndromes [48] and statins to treat high cholesterol levels in
the blood [49]. In the above mentioned examples, the prodrug moiety was attached to the
hydroxyl group of the active drug such that the drug promoiety (prodrug) has the potential
to degrade upon exposure to physiological environment such as stomach, intestine, and/or
blood circulation,  with  rates  that  are  solely  dependent  on the  structural  features  of  the
pharmacologically inactive promoiety (Kirby’s enzyme model). Other different linkers such
as Kirby’s maleamic acid enzyme model [50] was also investigated for the design of some
prodrugs such as tranexamic acid prodrugs to treat bleeding conditions [51] and acyclo‐
vir as anti-viral drug to treat Herpes Simplex [52]. Menger’s Kemp acid enzyme model [53]
was also utilized for  the design of  dopamine prodrugs for  the treatment of  Parkinson’s
disease  [54].  Prodrugs  for  dimethyl  fumarate  to  treat  psoriasis  were  also  designed,
synthesized and currently under in vitro and in vivo kinetic studies [55].
The same approach was utilized for masking the bitter taste of antibacterial drugs such as
cefuroxime (28) (Figure 4), atenolol (29) (Figure 4), paracetamol (30) (Figure 4), amoxicil‐
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lin  (15)  (Figure 2)  and cephalexin (31)  (Figure 4)  [56].  The role  of  the  promoiety in  the
antibacterial (cefuroxime) prodrugs is to block the free amine or the hydroxyl group which
is responsible for the drug bitter taste, and to enable the release of a drug in a programma‐
ble manner. The only difference between the proposed prodrugs and their parent drugs is
that the amine group in the parent drug is replaced with an amide moiety. Replacing the
amine group with an amide eliminate the capability of the molecule to hydrogen bond with
the  bitter  taste  receptor,  thus  masking the  bitter  taste  of  the  parent  drug.  For  example,
paracetamol, a widely used pain killer and fever-reducer found in the urine of patients who
had taken phenacetin (32) (Figure 4) has a very unpleasant bitter taste. Phenacetin, on the
other hand, lacks or has very slight bitterness. The difference in the structural features of
both drugs is only in the nature of the group in the para position of the benzene ring. While
in the case of paracetamol the group is hydroxyl,  in phenacetin it  is ethoxy. Acetanilide
(33) (Figure 4) has a chemical structure similar to that of paracetamol and phenacetin but
lacks  the group in the para  position of  the benzene ring,  making it  lack the bitter  taste
characteristic of paracetamol. These combined facts suggest that the presence of the hydroxy
group on the para position of paracetamol is the major contributor for its bitter taste. It is
believed that  paracetamol  interacts  with the bitter  taste  receptors  via  hydrogen bonding
which  involves  its  phenolic  group.  Blocking  the  phenolic  hydroxyl  of  paracetamol  is
expected  to  inhibit  its  binding  to  the  bitter  taste  receptor  and  hence  to  eliminate  its
bitterness. Similarly, it is expected that blocking the free amine group in atenolol, amoxicil‐
lin or  cephalexin with a  suitable  linker might  inhibit  the interaction between the amine
group of the parent drug and its bitter taste receptors and hence masks its bitterness. The
nature of the bitter taste receptors with paracetamol (via the phenolic group) or atenolol,
amoxicillin  or  cephalexin  (via  the  amine  group)  is  likely  to  be  as  a  result  of  hydrogen
bonding between the substrate and the receptor.
In this chapter, the novel prodrug approach to be presented is based on enzyme models that
have been made to understand the mechanism by which enzymes catalyze biochemical
reactions. The tool exploited in the design is computational calculations using molecular
orbital and molecular mechanics methods and correlations between experimental and
calculated rate values for some intramolecular processes. In this approach, no enzyme is
needed to catalyze the conversion of a prodrug to its active parent drug. The conversion rate
is solely determined by the factors affecting the rate limiting step in the intramolecular
(conversion) process. Knowledge gained from the mechanisms of the previously studied
enzyme models was exploited in the design.
It is believed that the use of this approach might eliminate all disadvantages related to prodrug
conversion by the metabolic (enzyme catalyzed process) approach. The bioconversion of
prodrugs is perhaps the most vulnerable link in the chain, because there are many intrinsic
and extrinsic factors that can affect the process. For example, the activity of many prodrug
activating enzymes may be varied due to genetic polymorphisms, age-related physiological
changes, or drug interactions, leading to adverse pharmacokinetic, pharmacodynamic, and
clinical effects. In addition, there are wide interspecies variations in both the expression and
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function of the major enzymes activating prodrugs, and these can pose some obstacles in the
preclinical optimization phase.
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5. Enzyme models utilized for the design of potential bitterless prodrugs
for bitter drugs such as atenolol, amoxicillin, cephalexin, paracetamol and
guaiphenesin
Scholar studies of enzyme mechanisms by several chemists and biochemists, over the past five
decades, have had a significant contribution for understanding the mode and scope of enzymes
catalysis.
Nowadays, the scientific community has reached to the conclusion that enzyme catalysis is
based on the combined effects of the catalysis by functional groups and the ability to reroute
intermolecular reactions through alternative pathways by which substrates can bind to
preorganized active sites. It is believed that rate accelerations by enzymes can be proceed by
(i) covalently enforced proximity, as seen in the case of chymotrypsin, [57] (ii) non-covalently
enforced proximity, as represented in the catalysis of metallo-enzymes, [58] (iii) covalently
enforced strain, [59], and (iv) non-covalently enforced strain, which has been extensively
studied on models mimicking the lysozyme enzyme which is most closely associated with rate
acceleration due to this kind of strain [60].
Rates for the majority of enzymatic reactions ranges between 1010 and 1018 fold their non-
enzymatic  bimolecular  counterparts.  For  instance,  biochemical  reactions  involving  the
catalysis  of  the enzyme cyclophilin  are  enhanced by105  and those by the enzyme oroti‐
dine monophosphate decarboxylase are accelerated by 1017  [61].  The significant enhance‐
ment in rate manifested by enzymes is a result of the substrate binding within the confines
of the enzyme active site.  The substrate-enzyme binding energy is the dominant driving
force  and  the  major  contributor  to  catalysis.  A  consensus  has  been  reached  that  in  all
enzymatic  processes  binding  energy  is  used  to  overcome  physical  and  thermodynamic
factors that make barriers to the reaction (free energy). These factors are: (1) the change in
entropy (ΔS˚), in the form of the freedom of motions of the reactants in solution; (2) the
hydrogen bonding net around bio-molecules in aqueous solution; (3) a proper alignment
of catalytic functional groups on the enzyme; and (4) the distortion of a substrate that must
occur before the reaction takes place [62,63].
Scholarly studies have been done by Bruice, Cohen, Menger, Kirby and others to design
enzyme models having the potential to reach rates comparable to rates of biochemical reactions
catalyzed by enzymes. Examples for such models are those based on rate enhancements driven
by covalently enforced proximity. The most cited example is the intramolecular cyclization of
dicarboxylic semi esters to anhydrides advocated by Bruice et al.[64,65]. Bruice et al. has
demonstrated that a relative rate of anhydride formation can reach 5 x 107 upon cyclization of
a dicarboxylic semi ester when compared to a similar counterpart’s bimolecular process.
Other examples of rate acceleration based on proximity orientation include: (a) acid-catalyzed
lactonization of hydroxy-acids as studied by Cohen et al.[66-68] and Menger [63, 69-75], (b)
intramolecular SN2-based cyclization reactions as researched by Brown et al. [76] and Mando‐
lini’s group [77], (c) proton transfer between two oxygens in Kirby’s acetals [78-84], and proton
transfer between nitrogen and oxygen in Kirby’s enzyme models [78-84], (d) proton transfer
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between two oxygens in rigid systems as investigated by Menger [63, 69-75],and (e) proton
transfer from oxygen to carbon in some of Kirby’s enol ethers [78-84]. The conclusions emerged
from these studies are (1) the driving force for enhancements in rate for intramolecular
processes are both entropy and enthalpy effects. In the cases by which enthalpy effects were
predominant such as ring-closing and proton transfer reactions proximity or/and steric effects
were the driving force for rate accelerations. (2) The nature of the reaction being intermolecular
or intramolecular is determined on the distance between the two reacting centers. (3) In SN2-
based ring-closing reactions leading to three-, four-and five-member rings the gem-dialkyl
effect is more dominant in processes involving the formation of an unstrained five-member
ring, and the need for directional flexibility decreases as the size of the ring being formed
increases. (4) Accelerations in the rate for intramolecular reactions are a result of both entropy
and enthalpy factors. (5) An efficient proton transfer between two oxygens and between
nitrogen and oxygen in Kirby’s acetal systems were affordable when a strong hydrogen
bonding was developed in the products and the transition states leading to them [85-103].
In the past few years some prodrugs based on the trimethyl lock system have been reported.
Borchardt et  al.  has shown that  the pro–prodrug 3-(2’-acetoxy-4’,  6’-dimethyl  dimethyl)-
phenyl-3, 3-dimethylpropionamide is capable of releasing the biologically active amine drug
upon acetate  hydrolysis  by enzyme triggering.  Another  successful  example  exploiting a
stereopopulation  control  model  is  the  prodrug  Taxol  which  enhances  the  drug  water
solubility  and  hence  affords  it  to  be  administered  to  the  human  body  via  intravenous
injection. Taxol is the brand name for paclitaxel, a natural diterpene, approved in the USA
for use to treat cancer [104-108].
6. Computational methods used in the design of bitterless prodrugs for
bitter tastant drugs
Nearly sixty five years ago, organic, bioorganic and medicinal chemists alike have started using
computational methods for calculating molecular properties of ground and transition states.
These computational methods use principles of computer science to aid in solving chemical
problems. Theoretical results emerged from these methods, incorporated into efficient
computer programs, for calculating the structures and physical and chemical properties of
molecules.
Equilibriums energy-based and reactions rates calculations for systems having medicinal
interests are of a vast importance to the health community. Today, quantum mechanics (QM)
such as ab initio, semi-empirical and density functional theory (DFT), and molecular mechanics
(MM) are commonly and increasingly being used and broadly accepted as precise tools for
predicting structure-energy calculations for drugs and prodrugs alike [109-112].
Ab initio methods typically are adequate only for small systems. Ab initio methods are based
entirely on theory from first principles. The ab initio molecular orbital methods (QM) such as
HF, G1, G2, G2MP2, MP2 and MP3 are based on rigorous use of the Schrodinger equation with
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a number of approximations. Ab initio electronic structure methods have the advantage that
they can be made to converge to the exact solution, when all approximations are sufficiently
small in magnitude and when the finite set of basis functions tends toward the limit of a
complete set. The convergence is usually not monotonic, and sometimes the smallest calcula‐
tion gives the best result for some properties. The disadvantage of ab initio methods is their
enormous computational cost. They take a significant amount of computer time, memory, and
disk space [109-112]. On the other hand, empirical or semi-empirical methods are less accurate
because they employ experimental results, often from acceptable models of atoms or related
molecules, to approximate some elements of the underlying theory. Example for such methods
is the semi-empirical quantum chemistry methods based on the Hartree–Fock formalism, but
make many approximations and obtain some parameters from empirical data. These methods
are especially important for calculating large molecules where the full Hartree–Fock method
without the approximations is too expensive. Semi-empirical calculations are much faster than
their ab initio counterparts. Their results, however, can be imprecise if the molecule being
computed is not similar enough to the molecules in the database used to parameterize the
method. Among the commonly used semiempirical methods are MINDO, MNDO,
MINDO/3, AM1, PM3 and SAM1. Calculations of molecules exceeding 60 atoms can be
handled using semiempirical methods [113-116].
Another widely used quantum mechanical method is the density functional theory (DFT).
With this theory, the properties of many-electron systems can be determined by using
functionals, i.e. functions of another function, which in this case is the spatially dependent
electron density. Therefore, the name density functional theory comes from the use of
functionals of the electron density. DFT is among the most popular and versatile methods
available in condensed-matter physics, computational physics, and computational chemistry.
The DFT method is adequate for calculating structures and energies for medium-sized systems
(30-60 atoms) of biological, pharmaceutical and medicinal interest and is not restricted to the
second row of the periodic table [43].
Although the use of DFT method is significantly increasing some difficulties still encountered
when describing intermolecular interactions, especially van der Waals forces (dispersion);
charge transfer excitations; transition states, global potential energy surfaces and some other
strongly correlated systems. Incomplete treatment of dispersion can adversely affect the DFT
degree of accuracy in the treatment of systems which are dominated by dispersion.
On the other hand, molecular mechanics is a mathematical approach used for the computation
of structures, energy, dipole moment, and other physical properties. It is widely used in
calculating many diverse biological and chemical systems such as proteins, large crystal
structures, and relatively large solvated systems. However, this method is limited by the
determination of parameters such as the large number of unique torsion angles present in
structurally diverse molecules [117].
Molecular mechanics simulations, for example, use a single classical expression for the energy
of a compound, for instance the harmonic oscillator. The database of compounds used for
parameterization, i.e., the resulting set of parameters and functions is called the force field, is
crucial to the success of molecular mechanics calculations. A force field parameterized against
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a specific class of molecules, for instance proteins, would be expected to only have any
relevance when describing other molecules of the same class. These methods can be applied
to proteins and other large biological molecules, and allow studies of the approach and docking
of potential drug molecules Since the size of the system which ab initio calculations can handle
is relatively small despite the large sizes of biomacromolecules surrounding solvent water
molecules such as in the cases of enzymes and receptors, isolated models of areas of proteins
such as active sites have been investigated using ab initio calculations. However, the disre‐
garded proteins and solvent surrounding the catalytic centers have also been shown to
contribute to the regulation of electronic structures and geometries of the regions of interest.
To overcome these discrepancies, quantum mechanics/molecular mechanics (QM/MM)
calculations are used, in which the system is divided into QM and MM regions where QM
regions correspond to active sites to be studied and are described quantum mechanically. MM
regions correspond to the remainder of the system and are treated molecular mechanically.
The pioneer work of the QM/MM method was accomplished by Warshel and Levitt [118], and
since then, there has been a significant progress on the development of a QM/MM algorithm
and applications to biological systems [119,120].
7. Mechanistic study of the acid-catalyzed hydrolysis of maleamic acids
34-42 used for the design of atenolol, amoxicillin and cephalexin prodrugs
The acid-catalyzed hydrolysis of 34-42 (Figure 5) was kinetically investigated by Kirby et al.
[84]. The study demonstrated that the amide bond cleavage is due to intramolecular nucleo‐
philic catalysis by the adjacent carboxylic acid group and the rate-limiting step is the tetrahe‐
dral intermediate breakdown (Figure 6) [84]. In 1996, the reaction was computationally
investigated by Katagi using AM1 semiempirical calculations. In contrast to what was
suggested by Kirby, Katagi’s study demonstrated that the rate-limiting step is the formation
of the tetrahedral intermediate and not its dissociation [121]. Later on Kluger and Chin have
experimentally researched the mechanism of the intramolecular hydrolysis process utilizing
several N-alkylmaleamic acids derived from aliphatic amines with a wide range of basicity
[122]. The study findings demonstrated that the identity of the rate-limiting step is a function
of both the basicity of the leaving group and the solution acidity.
In order to utilize Kirby’s enzyme model [84] for the design of prodrugs of the following drugs:
atenolol, amoxicillin and cephalexin, a mechanistic study using DFT calculation methods at
B3LYP/6-31G (d,p), B3LYP/311+G (d,p) levels and hybrid GGA (MPW1k) on an intramolecular
acid catalyzed hydrolysis of maleamic (4-amino-4-oxo-2-butenoic) acids (Kirby’s N-alkylma‐
leamic acids) 34-42 was conducted. The calculations confirmed that the reaction involves three
steps:(1) proton transfer from the carboxylic group to the adjacent amide carbonyl oxygen, (2)
nucleophilic attack of the carboxylate anion onto the protonated carbonyl carbon; and (3)
dissociation of the tetrahedral intermediate to provide products (Figure 6). Moreover, the
calculations demonstrate that the rate-limiting step is dependent on the reaction medium.
When the calculations were run in the gas phase the rate-limiting step was the tetrahedral
intermediate formation, whereas when the calculations were conducted in the presence of a
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cluster of water the dissociation of the tetrahedral intermediate was the rate-limiting step.
When the leaving group (methylamine) in 34-42 was replaced with a group having a low pKa
value the rate-limiting step of the hydrolysis in water was the formation of the tetrahedral
intermediate. In addition, the calculations revealed that the efficiency of the intramolecular
acid-catalyzed hydrolysis by the carboxyl group is remarkably sensitive to the pattern of
substitution on the carbon–carbon double bond. The rate of hydrolysis was found to be linearly
correlated with the strain energy of the tetrahedral intermediate or the product. Systems
having strained tetrahedral intermediates or products experience low rates and vice versa
[51,52,54,91].
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Figure 5. Acid-catalyzed hydrolysis of maleamic acids 34-42.
8. Bitterless atenolol prodrugs based on Kirby’s maleamic acids enzyme
model
Atenolol is a relatively polar hydrophilic compound with water solubility of 26.5 mg/mL at 37
0C and a log partition coefficient (octanol/ water) of 0.23. Atenolol is a selective ß1-adrenoceptor
antagonist, applied in the treatment hypertension, angina, acute myocardial infarction,
supraventricular tachycardia, ventricular tachycardia, and the symptoms of alcohol with‐
drawal. The net effect of atenolol on controlling both the heart rate and blood pressure is the
reduction in myocardial work and oxygen requirement which reduces cardiovascular stress,
thereby preventing arrhythmia and angina attacks.
Atenolol has a pKa of 9.6; it undergoes ionization in the stomach and intestine thus its oral
bioavailability is low due to inefficient absorption through membranes.
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The bioavailability of atenolol is 45%-55% of the given dose and is not increased by adminis‐
tration of the drug in a solution form [123-125].About 50% of administered atenolol is absorbed;
however, most of the absorbed quantity reaches the systemic circulation. Atenolol peak blood
levels are reached within two to four hours after ingestion. Differently from propranolol or
metoprolol, atenolol is resistant to metabolism by the liver and the absorbed dose is eliminated
by renal excretion. More than 85% of I.V. dose is excreted in urine within 24 hours compared
with 50% for an oral dose. Only 6-16% is protein-bound resulting in relatively consistent
plasma drug levels with about a four-fold inter-patient variation. The elimination half-life of
atenolol is between 6 to 7 hours and there is no alteration of kinetic profile of a drug by chronic
administration.
Atenolol is one of the most important medicines used for prevention of several types of
arrhythmias in childhood, but unfortunately it is still unlicensed [126]. On the other hand,
atenolol is indicated as a first-step therapy for hypertension in elderly patients, who have
difficulty in swallowing and, thus, tablets and capsules are frequently avoided.
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Atenolol is available as 25, 50 and 100 mg tablets for oral administration. However, most of
these medicines are not formulated for easy or accurate administration to children for the
migraine indication or in elderly patients who may have a difficulty swallowing tablets.
Attempts to prepare a liquid formulation was challenging because atenolol is unstable in
solutions. Studies showed that the degradation rate of atenolol is dependent on the tempera‐
ture, indicating higher stability at 4 ºC. Atenolol syrup is stable only for 9 days. Furthermore,
oral doses of atenolol are incompletely absorbed (range 46-62%), even when formulated as a
solution. Furthermore, atenolol bitterness is considered as a great challenge to health sector
when used among children and geriatrics [125]. The main problem in oral administration of
bitter drugs such as atenolol is incompliance by the patients [1] and this can be overcome by
masking the bitterness of a drug either by decreasing its oral solubility on ingestion or
eliminating the interaction of drug particles to taste buds [2].Thus the development of bitterless
and more lipophilic prodrug that is stable in aqueous medium is a significant challenge.
Improvement of atenolol pharmacokinetic absorption properties and hence its effectiveness
may increase the absorption of the drug via a variety of administration routes. The aims of the
study described in this section were: (1) design of atenolol prodrugs that can be (i) formulated
in aqueous solutions and be stable over a long period of time, (ii) bitterless compounds having
the capability to convert in physiological environment to the parent active drug, atenolol, in a
controlled manner and (2) synthesis, characterization and in vitro kinetic study of the conver‐
sion of the designed prodrugs to their parent drug in different pHs (physiological media).
The proposed atenolol prodrugs that were designed based on the acid-catalyzed hydrolysis
reactions of N-alkyl maleamic acids 34-42 (Figure 5)are depicted in Figure 7.
As shown in Figure 7, the only difference exists between the proposed atenolol prodrugs and
their parent drug is that the amine group of atenolol was replaced with an amide moiety.
Replacing the free amine in atenolol with an amide is expected to increase the stability of the
prodrug thus formed due to general chemical stability for tertiary alcohols over amine alcohols.
In addition, recent stability studies on atenolol esters have demonstrated that the esters were
more stable than their corresponding alcohol, atenolol, when formulating in aqueous solu‐
tions. Furthermore, kinetic study on atenolol and propranolol demonstrated that increasing
the lipophilicity of the drug leads to an increase in the stability of its aqueous solutions. Based
on that, it is expected that atenolol prodrugs shown in Figure 7 will have the potential to be
more resistant to heat or/oxidation when formulated in aqueous solutions [128-131]. Atenolol’s
bitter-taste can be masked by using the prodrug chemical approach. For example, paracetamol
(30), a widely used pain killer found in the urine of patients who had taken phenacetin has a
very unpleasant bitter taste. Phenacetin (31), on the other hand, lacks or has very slight bitter
taste. The difference in the structural features of both drugs is only the group in the para
position of the benzene ring. While in the case of paracetamol the group is hydroxyl, in
phenacetin it is ethoxy. On the other hand, acetanilide (32)is a bitterless compound with a
chemical structure similar to that of paracetamol and phenacetin but lacks the group in the
para position of the benzene ring. These facts suggest that the presence of the hydroxyl group
on the para position of the benzene ring is the major contributor for the bitterness of parace‐
tamol. It is likely that paracetamol bitterness is a result of interactions via hydrogen bonding
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of the phenolic group in paracetamol with the bitter taste receptors. Similarly, it is expected
that blocking the amine group in atenolol with a suitable linker might inhibit the hydrogen
bonding between the amine group in atenolol and its bitter taste receptors and hence masking
the drug’s bitterness [132].
The proposed atenolol prodrugs, atenolol ProD 1 and atenolol ProD 2, have a hydroxyl and
carboxylic acid groups (hydrophilic moiety) and the rest of the prodrug molecule is a lipophilic
moiety (Figure 7), where the combination of both groups ensures a moderate hydrophilic
lipophilic balance (HLB).
It is worth noting that the HLB value of atenolol prodrug will be largely determined on the
pH of the physiological environment by which the prodrug is exposed to. For example, in the
stomach pH, the atenolol prodrugs, ProD 1 and ProD 2, will exist in the free carboxylic acid
form whereas in the blood circulation the carboxylate form will be dominant. It was planned
that atenolol ProD 1-ProD 2 (Figure 7) will be formulated as sodium salts since the carboxylate
form is expected to be quite stable in neutral aqueous medium. However, upon dissolution in
the stomach (pH less than 3) the proposed prodrugs will exist mainly as a carboxylic acid form
thus enabling the acid-catalyzed hydrolysis to commence.
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9. Calculation of the t1/2 values for the cleavage reactions of atenolol
prodrugs ProD 1-2
The effective molarity (EM) parameter is a commonly tool used to predict the efficiency of
intramolecular reactions when bringing two functional groups such as an electrophile and a
nucleophile in a close proximity. Intramolecularity is usually measured by the effective
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molarity parameter. The effective molarity is defined as the rate ratio (kintra/kinter) for corre‐
sponding intramolecular and intermolecular processes driven by identical mechanisms. Ring
size, solvent and reaction type are the major factors affecting the EM value. Ring-closing
reactions via intramolecular nucleophilic addition are much more efficient than intramolecular
proton transfer reactions. EM values in the order of 109-1013 M were determined for intramo‐
lecular processes occurring through nucleophilic addition. Whereas for proton transfer
processes values of less than 10 M were measured for proton transfer processes until recently
where values of 1010 was documented by Kirby on the hydrolysis of some enzyme models
[60,78-84].
For obtaining the EM values for processes 34-42 and atenolol ProD1-2 the kinetic and ther‐
modynamic parameters for their corresponding intermolecular process, Inter (Figure 8) were
calculated.
Using equations 1-4, equation 5 was derived, and describes the EM term as a function of the
difference in the activation energies of the intra-and the corresponding inter-molecular
processes. The calculated EM values for processes 34-42 and ProD 1-2 were calculated using
equation 5.
intra interEM = k /k (1)
‡
inter interΔG = -RT ln k (2)
‡
intra intraΔG = -RT ln k (3)
‡ ‡
intra inter intra interΔG - ΔG = -RT ln k /k (4)
ln EM =-(ΔG‡intra- ΔG‡inter)/RT (5)
Where T is the temperature in Kelvin and R is the gas constant.O
NHCH3
CH3 Inter
O
CH3
OHCH3COOH NH2CH3
H2O
Figure 8. Acid catalyzed hydrolysis for process Inter.
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The calculated EM values from eq. 5 for processes34-38 were correlated with the corresponding
EM values [101] (Figure 9a). Good correlation with a correlation coefficient of r=was obtained.
The correlation results demonstrate that processes 35 and 37werethe most efficient among
34-38, whereas process 4 was the least. The discrepancy in the rates of processes 35 and 38on
one hand and process 37 on the other hand is might be attributed to strain effects.
In addition, for further support to the credibility of our DFT calculations the calculated free
activation energies (∆GBW‡) were correlated with the corresponding experimental free activa‐
tion energies (Exp ∆G‡). Good correlation was obtained with R value of 0.96 (Figure 9b).
Utilizing eq. 6 obtained from the correlation of log krelvs. ∆G‡ and the experimental t1/2 value
measured for process 2 (t1/2=1 second) [103], the t1/2 values for atenolol ProD 1 and atenolol
ProD 2 at pH 2 were calculated and their values were65.3 hours and 11.8 minutes, respectively.
‡   0.44  13.53= - D +rellog k G (6)
10. In vitro intraconversion of atenolol ProD 1 to the parent drug atenolol
Kinetics of the acid-catalyzed hydrolysis for atenolol ProD 1 was carried out in an aqueous
buffer in a similar manner to that done by Kirby on N-alkylmaleamic acids 34-38. This is in
order to examine whether atenolol prodrug is hydrolyzed in aqueous medium and to what
extent, suggesting its fate in the system. Acid-catalyzed hydrolysis of atenolol ProD 1 was
investigated in four different aqueous media: 1 N HCl and buffers pH 2, pH 5 and pH 7.4.
Under the experimental conditions, atenolol ProD 1 was hydrolyzed to release the parent drug,
atenolol, (Figure 10) as was evident by HPLC measurements. At constant pH and temperature,
the reaction displayed strict first order kinetics as the kobs was fairly constant and a straight line
was obtained on plotting log concentration of residual atenolol prodrug verses time. The rate
constant (kobs) and the corresponding half-lives (t1/2) for atenolol prodrug ProD 1 in the different
media were calculated from the linear regression equation correlating the log concentration of
the residual prodrug verses time. The kinetic data, kobs and t1/2 values, are listed in Table 1. 1N
HCl, pH 2 and pH 5 were selected to examine the intraconversion of atenolol ProD 1in pH as
of stomach, because the mean fasting stomach pH of adult is approximately 1-2 and increases
up to 5 following ingestion of food. In addition, buffer pH 5 mimics the beginning of the small
intestine environment. The medium at pH 7.4 was selected to examine the intraconversion of
the tested prodrug in the blood circulation system. Acid-catalyzed hydrolysis of atenolol ProD
1 was found to be higher in 1N HCl than at pH 2 and 5 (Figure 10). At 1N HCl atenolol ProD
1 was intraconverted to release the parent drug in 2.53 hour. On the other hand, at pH 7.4, the
prodrug was entirely stable and no release of the parent drug was observed. Since the pKa of
the carboxylic group of atenolol ProD1 is in the range of 3-4, it is expected at pH 5 the anionic
form of the prodrug will be dominant and the percentage of the free acid form that expected
to undergo hydrolysis will be relatively low. At 1N HCl and pH 2 most of the prodrug will
exist as the free acid form, whereas at pH 7.4 most of the prodrug will be in the anionic form.
Thus, the difference in rates at the different pH buffers.
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Figure 9. (a) log calculated effective molarity vs. experimental effective molarity for processes 34-38. (b) DFT calculat‐
ed activation energy (kcal/mol) vs. experimental activation energy (kcal/mol) for processes 34-38.
Figure 10. First order hydrolysis plot of atenolol ProD 1 in (a) 1N HCl, (b) buffer pH 2 and (c) buffer pH 5.
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t 1/2 (h) k obs (h-1) Medium
2.53 4.95 x 10 -4 1 N HCl
3.82 2.22 x 10 -4 Buffer pH 2
133 2.75 x 10-6 Buffer pH 5
----- No Reaction Buffer pH 7.4
In 1N HCl and at pH 2, 5 and 7.4
Table 1. The observed k value and t1/2 of atenolol ProD 1
11. Bitterless amoxicillin and cephalexin prodrugs based on Kirby’s
maleamic acids enzyme model
Most of the antibacterial agents that are commonly used suffer unpleasant taste and a respected
number of them are characterized with bitter taste. For example, amoxicillin, cephalexin and
cefuroxime axetil have an extremely unpleasant and bitter taste which is difficult to mask. This
is a particular problem in geriatric patients who cannot swallow whole tablets or when small
doses are required. Even the antibacterial suspension is difficult for pediatrics to administer
due to its better and unpleasant taste [133-139].
It is widely assumed that the extremely bitter and unpleasant taste of these antibacterial drugs
is due to a formation of intermolecular force/s between the drug and the active site of the bitter
taste receptor/s. The intermolecular bond/s is/are most likely due to formation either via
hydrogen bond or ionic bond of the amido (in cefuroxime)or amine (in amoxicillin and
cephalexin) group to the active site of the bitter taste receptors.
Antimicrobial agents are classified according to their specific mode of action against bacterial
cell. By which these agents may interfere with cell wall synthesis, inhibit protein synthesis,
interfere with nucleic acid synthesis or inhibit a metabolic pathway. They have a broad
spectrum of activity against both gram-positive and gram-negative bacteria. Among these
agents, β-lactams – penicillins, cephalosporins, carbapenems and monobactams, by which
represent 60% of all antimicrobial use by weight. They are preferred because of their efficacy,
safety, and because their activity can be extended or restored by chemical manipulation.
Inevitably, however, their usage has been restricted because of their bacterial resistance.
11.1. Amoxicillin
Amoxicillin is an oral semi-synthetic penicillin, moderate-spectrum, bacteriolytic, β-lactam
antibiotic used to treat bacterial infections caused by susceptible microorganisms by which it
is susceptible to the action of the β-lactamases. Amoxicillin has a bactericidal action and acts
against both Gram positive and Gram-negative microorganisms by inhibiting the biosynthesis
and repair of the bacterial mucopeptide wall. It is usually the drug of choice within its class
because it is well absorbed following oral administration. Amoxicillin presents some out‐
standing advantages in comparison with other amino-penicillins, such as: a better absorption
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from the intestinal tract, better capacity for reaching effective concentrations at the sites of
action and a more rapid capacity for penetrating the cellular wall of Gram-negative microor‐
ganisms. Amino-penicillins are frequently prescribed agents for the oral treatment of lower
respiratory tract infections and are generally highly effective against S. pneumonia and non-
β-lactamase-producing H. influenza. Amoxicillin is mostly common antibiotics prescribed for
children. It has high absorption after oral administration which is not altered and affected by
the presence of food. Amoxicillin dose reaches Cmax about 2 hours after administration and is
quickly distributed and eliminated by excretion in urine (about 60%-75%). The antibacterial
effect of amoxicillin is extended by the presence of a benzyl ring in the side chain. Because
amoxicillin is susceptible to degradation by β-lactamase-producing bacteria, which are
resistant to a broad spectrum of β-lactam antibiotics, such as penicillin, for this reason, it is
often combined with clavulanic acid, a β-lactamase inhibitor. This increases effectiveness by
reducing its susceptibility to β-lactamase resistance. Amoxicillin has two ionizable groups in
the physiological range (the amino group in α-position to the amide carbonyl group and the
carboxyl group). Amoxicillin has a good pharmacokinetics profile with bioavailability of 95%
if taken orally, its half-life is 61.3 minutes and it is excreted by the renal and less than 30 % bio-
transformed in the liver [140-142].
11.2. Cephalexin
Cephalexin is a first-generation cephalosporin antibiotic, which was chosen as the model drug
candidate  to  obtain  dosage  with  improved stability,  palatability  and attractive  pediatric
elegance, cost effective with ease of administration. Cephalosporins are the most widely used
for treatment of skin infections because of their safety profile, and their wide range of activity
against both gram positive and gram negative microorganism. Cephalexin is also used for the
treatment of articular infections as a rational first-line treatment for cellulitis, it is a useful
alternative to penicillins hypersensitivity, and thought to be safe in a patient with penicillin
allergy but caution should always be taken, that’s because cephalexin and other first-genera‐
tion cephalosporins are known to have a modest cross-allergy in patients with penicillin
hypersensitivity. In addition, cephalexin is also effective and used in the treatment of group A
β-hemolytic streptococcal throat infections. Cephalexin works by interfering with the bacter‐
ia's cell wall formation, causing it to rupture, and thus killing the bacteria. The compound is
zwitterion by which it contains both a basic and an acidic group, the isoelectric point of cephalexin
in water is approximately 4.5 to 5. Cephalexin has a good pharmacokinetic profile by which it
is well absorbed, 80% excreted unchanged in urine within 6 hours of administration. Cephalex‐
in’s half-life is 0.5-1.2 hours and it is excreted via the renal. It is used for the treatment of infections
including otitis media, streptococcal pharyngitis, bone and joint infections, pneumonia, cellulitis
and UTI, and so it may be used to prevent bacterial endocarditis [142-145].
11.3. Cefuroxime axetil
Cefuroxime axetil is a semi-synthetic, broad-spectrum cephalosporin antibiotic for oral
administration. Cefuroxime axetil is an orally active antibacterial agent though its absorption
is incomplete. The range of its bioavailability is 25-52%. The axetil moiety is metabolized to
acetaldehyde and acetic acid. Peak plasma concentration is reached 2-3 hours after an oral
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administration. Up to 50% of cefuroxime in the circulation is bound to plasma proteins. The
plasma half-life is about 70 minutes and is prolonged in patients with renal impairments and
in neonates. Cefuroxime axetil is widely distributed in the body including plural fluid, sputum
bone synovial fluid, and aqueous humor, but only achieves therapeutic concentration in the
CSF when the meninges are inflamed. It crosses the placenta and has been detected in breast
milk. Cefuroxime is excreted unchanged, by glomerular filtration and renal tubular secretion,
and high concentration is achieved in urine [146].
Amoxicillin, cephalexin and cefuroxime axetil as mentioned before suffer low stability and
bitter taste sensation. Several attempts were made in order to enhance their aqueous solubility
and bioavailability. Among several research approaches, the prodrug approach has been
widely used for an improvement of drugs delivery to their site of action by physicochemical
modulation properties that affect absorption or by targeting to specific enzymes or membrane
transporters [147,148]. Generally, enzymatic catalysis is required for most of prodrugs that are
in clinical use in order to be converted into the parent drug. This is mostly particular for those
prodrugs designed to liberate the parent drug in the blood stream following gastro-intestinal
absorption. These prodrugs are typically ester derivatives of drugs containing carboxyl or
hydroxyl groups which are converted into the parent drug by esterase catalyzed hydrolysis.
However, a high chemical reactivity that precludes either liquid or solid formulation of the
prodrug (e.g. some phenol esters) or low chemical reactivity, resulting in reduced regeneration
of the parent drug due to enzymatic activation for other functional groups. Thus, non-
enzymatic pathways for some prodrugs that can regenerate the parent drug, have emerged as
an alternative approach by which prodrug activation is not influenced by inter-and intra-
individual variability that affects the enzymatic activity. In particular, since the middle-1980s,
cyclization-activated prodrugs have been capturing the attention of medicinal chemists, and
reached maturity in prodrug design in the late 1990s. Activation of prodrugs via a cyclization
pathway allows a fine tuning of the rate of drug release through the appropriate choice of the
functional groups involved in ring closure and stereoelectronic constraints in the course of the
cyclization step. As noticed from the history of prodrugs mostly in preclinical and clinical
consideration of prodrug bioconversion, the most common that several hydrolyses-activated
prodrugs of penicillins, cephalosporins, and angiotensin-converting enzyme inhibitors have
less than complete absorption which was observed and highlights yet another challenge with
prodrugs susceptible to esterase hydrolysis. The oral bioavailability of these mentioned types
of prodrugs is typically around 50% since these prodrugs undergo premature hydrolysis
during the absorption process in the enterocytes of the gastrointestinal tract [149]. Another
approach which has been utilized to enhance bioavailability of antibacterial drugs is by making
the corresponding prodrugs with optimum lipophilicity. Some drugs remain poorly absorbed
from most of the administration routes due to their poor lipophilicity. Two approaches were
utilized to enhance the bioavailability of antibacterial drugs by increasing their lipophilicity:
(a) membrane/water partition coefficient of the lipophilic form of a drug has been enhanced
as compared to the hydrophilic form, thus favoring passive diffusion such as in the cases of
pivampicillin, bacampicillin and talamipicillin (prodrugs of ampicillin)which are more
lipophilic and better absorbed than amoxicillin and are rapidly interconverted and (b) the
Application of Nanotechnology in Drug Delivery424
lipophilic prodrugs have poor solubility in gastric fluids and thus greater stability and
absorption example for such approach is erythromycin esters [150].
Some ampicillin esters were prepared for improving the bioavailability of ampicillin. For
example, the pivaloyloxyethyl (pivampicillin), phthalidyl (talampicillin), and ethoxycarbony‐
loxyethyl (bacampicillin)were found to have two fold the oral bioavailability of their parent
drug, ampicillin. Complete hydrolysis of these esters was occurred in the gastrointestinal
mucosa, whereas methoxymethyl ester of ampicillin was partially hydrolyzed by gut and hepatic
first-pass metabolism and appears in the systemic circulation and tissues as intact ester [151-154].
12. In vitro intraconversion of amoxicillin and cephalexin prodrugs to their
parent drugs
Based on our previously reported DFT calculations and on experimental data for the acid-
catalyzed hydrolysis of amide acids 34-42 (Figure 5) [84,91], two amoxicillin and cephalexin
prodrugs were proposed (Figures11 and 12, respectively). As shown in Figures11 and 12, the
antibacterial prodrugs, amoxicillin ProD 1 and cephalexin ProD 1 molecules are composed of
an amide acid promoiety, containing a carboxylic acid group (hydrophilic moiety) and the rest
of the antibacterial prodrug molecule (a lipophilic moiety).
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Figure 11. Acid-catalyzed hydrolysis of amoxicillin ProD 1.
The combination of both, the hydrophilic and lipophilic groups provides a prodrug entity with
a potential to be with a high permeability (a moderate HLB). It should be emphasized, that the
HLB value of the prodrug entity will be determined upon the pH of the target physiological
environment. In the stomach where the pH is in the range 1-2, it is expected that prodrugs,
amoxicillin ProD1 and cephalexin ProD1 will be in a free carboxylic acid form (a relatively
high hydrophobicity) whereas in the blood stream circulation where the is pH 7.4 a carboxylate
anion (a relatively low hydrophobicity) is expected to be predominant form. Our strategy was
to prepare amoxicillin ProD 1 and cephalexin ProD 1 as sodium or potassium carboxylates
due to their high stability in neutral aqueous medium. It should be indicated that compounds
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34-42 undergo a relatively fast hydrolysis in acidic aqueous medium whereas they are quite
stable at neutral pH.
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Figure 12. Acid-catalyzed hydrolysis of cephalexin ProD 1.
The hydrolysis kinetic studies for amoxicillin ProD 1 and cephalexin ProD 1 were carried
out in aqueous buffers in the same manner to that executed by Kirby et al.  on maleamic
acids 34-40. This is to investigate whether the antibacterial prodrugs undergo hydrolysis in
aqueous medium and to what  extent  or  not,  suggesting the fate  of  the prodrugs in the
system. The kinetics for the acid-catalyzed hydrolysis of the synthesized amoxicillin ProD
1 and cephalexin ProD 1 were carried out in four different aqueous media: 1 N HCl, buffer
pH  2.5,  buffer  pH  5  and  buffer  pH  7.4.  Under  the  experimental  conditions  the  two
antibacterial prodrugs intraconverted to release the parent drugs (Figures 13 and 14) as was
determined by HPLC analysis. For both amoxicillin and cephalexin prodrugs, at constant
temperature and pH the hydrolysis reaction displayed strict first order kinetics as the kobs
was quite constant and a straight line was obtained on plotting log concentration of residual
prodrug  verves  time.  The  rate  constant  (kobs)  and  the  corresponding  half-lives  (t1/2)  for
amoxicillin ProD 1and cephalexin ProD 1 in the different media were calculated from the
linear regression equation obtained from the correlation of log concentration of the residual
prodrug verses time.  The kinetic  data for amoxicillin ProD 1and cephalexin  ProD 1  are
listed in Tables 2 and 3, respectively. It is worth noting that 1N HCl, pH 2.5 and pH 5 were
selected to examine the intraconversion of amoxicillin ProD 1and cephalexin ProD 1 in the
pH as  of  stomach,  since  the  mean fasting  stomach pH of  adult  is  approximately  1-2.5.
Furthermore, environment of buffer pH 5 mimics that of beginning small intestine route,
whereas pH 7.4 was selected to determine the intraconversion of the tested prodrugs in
blood  circulation  system.  Acid-catalyzed  hydrolysis  of  both,  amoxicillin  ProD  1and
cephalexin ProD 1 was found to be much higher in 1N HCl than at pH 2.5 and 5 (Figures13
and  14).  At  1N  HCl  the  t  ½  values  for  the  intraconversion  of  amoxicillin  ProD  1and
cephalexin  ProD 1  were  about  2.5  hours.  On the  other  hand,  at  pH 7.4,  both prodrugs
amoxicillin ProD 1and cephalexin  ProD 1  were quite stable and no release of the parent
drugs  was  observed.  At  pH  5  the  hydrolysis  of  both  prodrugs  amoxicillin  ProD  1and
cephalexin  ProD  1  was  too  slow.  This  is  because  the  pKa  of  amoxicillin  ProD  1and
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cephalexin ProD 1 is in the range of 3-4, it is expected that at pH 5 the anionic form of the
prodrug will  be dominant and the percentage of the free acidic form that undergoes an
acid-catalyzed hydrolysis will be relatively low. At 1N HCl and pH 2.5 most of the prodrug
will exist as the free acid form and at pH 7.4 most of the prodrug will be in the anionic
form. Thus, the discrepancy in rates at the different pH buffers.
Figure 13. First order hydrolysis plot of amoxicillin ProD 1 in (a) 1N HCl, (b) buffer pH 2.5 and (c) buffer pH 5.
t 1/2 (h) k obs (h-1) Medium
2.5 2.33x10 -4 1 N HCl
7 9.60 x10 -5 Buffer pH 2.5
81 7.55x10-6 Buffer pH 5
---- No reaction Buffer pH 7.4
Table 2. The observed k value and t1/2 of amoxicillin ProD 1 in 1N HCl and at pH 2, 5 and 7.4
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t 1/2 (h) k obs (h-1) Medium
2.4 2.41x10 -4 1 N HCl
14 4.17x10 -5 Buffer pH 2.5
--- No reaction Buffer pH 5.5
--- No reaction Buffer pH 7.4
in 1N HCl and at pH 2, 5 and 7.4
Table 3. The observed k value and t1/2 of cephalexin ProD 1
Figure 14. First order hydrolysis plot of cephalexin ProD 1 in (a) 1N HCl, (b) buffer pH 2.5 and (c) buffer pH 5.
13. Mechanistic study of Bruice’s hydrolysis of di-carboxylic semi-esters
43-47 used for the design of bitterless paracetamol prodrugs
Five decades ago, Bruice and Pandit have investigated the kinetics of for the hydrolysis reaction
of di-carboxylic semi-esters 43-47 depicted in Figure 15 [64,65]. Their findings revealed the
relative rate (krel) for 47>46>45>44>43. They attributed the discrepancy in rates to differences
in the proximity orientation of the nucleophile to electrophile. Using the observation that alkyl
substituent on succinic acid influences rotamer distributions, the ratio between the reactive
gauche and the unreactive anti-conformers, they proposed that gem-dialkyl substitution
increased the probability of the resultant rotamer adopting the more reactive conformation.
Hence, for ring-closing reaction to precede, the two reacting centers, the nucleophile and
electrophile, must be in the gauche conformation. In the unsubstituted reactant, the nucleo‐
phile and electrophile are almost entirely in the anti-conformation in order to minimize steric
interactions [81-82]. In order to design paracetamol prodrugs, via linking the active drug with
a di-carboxylic semi-ester linker (Bruice’s enzyme model), lacking the bitterness of their parent
drug, paracetamol, and have the capability to chemically and not enzymatically undergo
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hydrolysis in physiological environment we have unraveled the mechanism for the ring-
closing reaction of 43-47 using DFT and molecular mechanics calculation methods [93].
Quantum molecular mechanics using DFT methods at B3LYP 6-31G (d,p) and B3LYP/311+G
(d,p) levels were exploited to calculate the thermodynamic and kinetic parameters for all
reactants, transition states, intermediates and products involved in the proposed mechanism
for process 43-47 (Figure 16). As shown in Figure 16 the mechanism for these processes consists
of two steps; (1) formation of a tetrahedral intermediate and (2) collapse of a tetrahedral
intermediate to furnish a cyclic anhydride and p-bromophenolate anion.
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Figure 15. Hydrolysis of di-carboxylic semi-esters 43-47.
The phenomenon of rate enhancements in several intramolecular processes was ascribed by
Bruice and Menger to the importance of the proximity of the nucleophile to the electrophile of
the ground state molecules [64,65,155]. Menger in his “spatiotemporal” hypothesis advocated
a mathematical equation correlating activation energy to distance and based on this that, he
came to the conclusion that enormous rate accelerations in reactions catalyzed by enzymes are
feasible when imposing short distances between the reactive centers of the substrate and
enzyme [155]. Differently from Menger, Bruice attributed the catalysis by enzymes to favorable
‘near attack conformations’; systems that have a high quota of near attack conformations will
have a higher intramolecular reaction rate and vice versa. Bruice’s idea invokes a combination
of distance between the two reacting centers and the angle of attack by which the nucleophile
approaches the electrophile [64,65].
In contrast to the proximity orientation proposal, others proposed the high rate enhancements
in intramolecular processes to steric effects (relief of the strain energy of the reactant) [156].
To test whether the acceleration in rates for processes 43-47 (Figure 15) is a result of proximity
orientation or due to steric effects (difference in strain energies of the reactants), the strain
energy values for the reactants and the intermediates in systems 43-47 were calculated using
Allinger’s MM2 method. The calculated strain energy values for 43-47 were correlated with
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the corresponding experimental relative rates (log krel) [64,65]. The results demonstrated good
correlation between the two parameters. On the other hand, attempts to correlate the distance
between the two reactive centers and log krel failed to provide any correlation between the two
parameters. This reveals that the driving force for acceleration in rates of 43-47 is driven by
strain effects and not proximity orientation stemming from Bruice’s near attack conformation
[64,65].In addition, in accordance with Bruice and Pandit’s findings [64,65] we have found that
the ring-closing reactions proceed by one mechanism, by which the rate-limiting step is the
tetrahedral intermediate dissociation and not its formation.
14. Paracetamol Prodrugs Based on Bruice’s Enzyme Model
Paracetamol is an odorless, bitter crystalline compound used as an over the counter analgesic
and anti-pyretic drug. Paracetamol is used to relief minor aches. it is used as pain killer by
decreasing the synthesis of prostaglandin due to inhibiting cyclooxygenases (COX-1 and
COX-2). Paracetamol is favored over aspirin as pain killer in patients have excessive gastric
secretion or prolonged bleeding. It was approved to be used as fever reducer in all ages.
Pharmacokinetic studies have shown that urine of patients who had taken phenacetin
contained paracetamol. Later was demonstrated that paracetamol was a urinary metabolite of
acetanilide. Phenacetin known historically to be one of the first non-opioid analgesics without
anti-inflammatory properties lacks or has a very slight bitter taste [157,158]. Comparison of
the structures of paracetamol and phenacetin shows that shows close similarity between both
analgesics except of the nature of the group on the para position of the benzene ring. While in
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Figure 16. Proposed mechanism for the hydrolysis of di-carboxylic semi-esters 43-47.
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paracetamol the group is hydroxyl, in phenacetin it is ethoxy. On the other hand, acetanilide
has a chemical structure similar to that of paracetamol and phenacetin but it lacks any group
at the para position of the benzene ring. Acetanilide lacks the bitter taste characteristic for
paracetamol. The comparisons of the three compounds might suggest that the presence of
hydroxy group on the para position of the benzene ring plays a major role for paracetamol
bitterness. Therefore, it is expected that masking the hydroxyl group in paracetamol with a
suitable linker could inhibit the binding of paracetamol to its bitter taste receptor/s and hence
masking its bitterness. It is likely that paracetamol binds to the active site of its bitter taste
receptor via hydrogen bonding interactions by which its phenolic hydroxyl group is engaged.
It is worth noting that linking paracetamol with Bruice’s enzyme model linker via its phenolic
hydroxyl group might hinder paracetamol bitter taste.
Based on the DFT calculations on the cyclization of Bruice’s 43-47 (Figure 15), two paracetamol
prodrugs were proposed (Figure 17). As shown in Figure 17, the paracetamol prodrugs, ProD
1-2,have a carboxylic acid group as a hydrophilic moiety and the rest of the prodrug, acetani‐
lide, as a lipophilic moiety, where the combination of both groups provides a moderate HLB.
It should be noted that the HLB value will be determined upon the physiologic environment
by which the prodrug is dissolved. For example, in the stomach, the paracetamol prodrugs
will primarily exist in the carboxylic acid form whereas in the blood circulation the carboxylate
anion form will be predominant. Since Bruice’s cyclization reaction occurs in basic medium
paracetamol ProD 1-2 were obtained as carboxylic free acid form, since this form is expected
to be stable in acidic medium such as the stomach.
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Figure 17. Hydrolysis of paracetamol ProD 1 and paracetamol Prod 2.
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15. In vitro intraconverion of Paracetamol ProD 1 to the parent drug
paracetamol
The hydrolysis of paracetamol ProD 1 was studied in four different media; 1N HCl, buffer pH
3, buffer pH 6.6 and buffer pH 7.4. The prodrug hydrolysis was monitored using HPLC
analysis. At constant pH and temperature the release of paracetamol from its prodrug was
followed and showed a first order kinetics. kobs (h-1) and t1/2 values for the intraconversion of
paracetamol ProD 1 was calculated from regression equation obtained from plotting log
concentration of residual of paracetamol ProD 1 vs. time. The kinetics results in the different
media are summarized in Table 4 and Figure 18.
Medium kobs (h-1) t½ (h)
1N HCl No reaction No reaction
Buffer pH 3 6.3 x 10-5 3
Buffer pH 7.4 6.1 x 10-4 0.3
Table 4. The observed k value and t1/2 of paracetamol ProD 1 In 1N HCl and buffers pH 3and 7.4.
As shown in Table 4 the hydrolysis rate of paracetamol ProD 1 at pH 7.4 was the fastest among
all media, followed by pH 6.6 medium. In 1N HCl no conversion of the prodrug to the parent
dug was observed.
Figure 18. First order hydrolysis plot of paracetamol ProD 1 in (a) buffer pH 3 and (b) buffer pH 7.4.
At pH 7.4 and 6.6 paracetamol ProD 1 is mainly exists as the carboxylate anion form which is
expected to undergo fast hydrolysis according to Bruice’s mechanism shown in Figure 16. At
pH 3, the prodrug exists in both form, the carboxylate anion and the carboxylic free acid forms
since the pKa of the prodrug is about 3. In 1N HCl, the prodrug is entirely exists as the
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carboxylic free acid form and since only the carboxylate anion form undergoes Bruice’s
cyclization the hydrolysis rate in 1N HCl is almost negligible or zero.
16. Conclusions and future directions
The quantum mechanics (QM) calculations in different methods revealed that the acid-
catalyzed hydrolysis efficiency of processes 34-42, atenolol ProD 1-ProD 2,amoxicillin ProD1
and cephalexin ProD 1 is significantly sensitive to the pattern of substitution on the carbon-
carbon double bond and nature of the amine leaving group. The linear correlation found
between the reaction rate and strain energy difference between the intermediate and the
reactant (Es INT-GM) supports the notion that the reaction is governed by strain effects.
Furthermore, the linear correlation of the calculated DFT and experimental EM values
reinforce the credibility of using DFT methods for energy and rate predictions for the kind of
processes reported in this section.
Comparisons of the calculated DFT properties for processes 34-40andatenolol prodrugs
ProD1-ProD2 with the calculated DFT properties for the acid-catalyzed hydrolysis of acyclovir
prodrugs and cefuroxime (Figure 19) demonstrate that while for processes 34-40 and atenolol
prodrugs ProD 1-ProD 2, the rate-limiting step was the collapse of the tetrahedral intermediate
in the processes of cefuroxime prodrugs and acyclovir prodrugs the rate-limiting step was the
tetrahedral intermediate formation. This is might attributed to the nature of the amine leaving
group involved in the tetrahedral intermediate collapse step.
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Figure 19. Chemical structures for acyclovir and cefuroxime prodrugs.
Comparison of the calculated t 1/2 value (63.2 hours) for atenolol ProD 1 to the experimental
value (3.82 hours) indicates that while the B3LYP/6-31G (d,p) value is overestimated (about 17
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times larger than the experimental) the one obtained by mpwpw91/6-31+G(d,p) was much
more closer (6.3 hours). The discrepancy between the calculated B3LYP/6-31G (d,p) and
experimental values might be attributed to (i) B3LYP/6-31 G(d,p) is a DFT method without
dispersion corrections and (ii) PCM solvation model (calculations in presence of solvent) is not
capable of handling calculations in acidic aqueous solvent.
The experimental t 1/2 value for atenolol ProD 1 at pH 5 was 133 hours and at pH 7.4 no
hydrolysis was observed. The lack of the hydrolysis at the latter pH might be due to the fact
that at this pH atenolol ProD 1 exists mainly in the ionized form (pKa about 3-4). As mentioned
before the free acid form is a mandatory requirement for the acid-catalyzed hydrolysis to
proceed.
In a similar manner to that observed in the intraconversion of atenolol ProD 1, the acid-
catalyzed hydrolysis of both, amoxicillin ProD 1and cephalexin ProD 1 was much faster in 1N
HCl than in pH 2.5 and 5 (Figures13 and 14). At 1N HCl the t ½ values for the intraconversion
of amoxicillin ProD 1and cephalexin ProD 1was in both cases about2.5hours. On the other
hand, in pH 7.4, both amoxicillin ProD 1and cephalexin ProD 1 were entirely stable and no
intraconversion to the parent drugs was detected. The salient points emerged from our study
on Bruice’s system are as follows: (i) the cyclization rate of Bruice’s system was found to be
dependent on the difference in the strain energies of the intermediate and reactant, and no
relationship was found between the reaction rate and the distance between the nucleophile
and the electrophile. (ii) The reactions of strained di-carboxylic semi-esters are more efficient
than the less strained ones, and the reactivity extent was linearly correlated with the strain
energy difference between the intermediate and reactant. (iii) The activation energy required
to give a stable transition state for a strained di-carboxylic semi-ester is less than that for the
unstrained semi-ester, since the conformational change from the reactant to the transition state
in the former is smaller, and (iv) based on the linearity found between the relative rate, the
activation energy and the difference in strain energies of the intermediate and reactant for
Bruice’s di-carboxylic semi-esters we have proposed two paracetamol prodrugs, which were
synthesized and their in vitro kinetics was studied. Future strategy to achieve more efficient
atenolol prodrugs capable of increasing the liquid formulation stability, eliminating atenolol
bitterness and releasing the parent drug in a programmable manner is synthesis of atenolol
prodrugs having pKa around 6 (intestine pH). At the pH of the intestine the planned prodrugs
will exist mainly in the acidic form which has the capability to undergo an acid-catalyzed
hydrolysis to provide the active drug, atenolol.
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